Arthritis & Rheumatology最新文献

Comparative Effectiveness of Abatacept versus Adalimumab in Shared Epitope positive and negative Rheumatoid Arthritis patients. 阿巴接受与阿达木单抗在共享表位阳性和阴性类风湿关节炎患者中的比较疗效。

IF 13.3 1区医学

Arthritis & Rheumatology Pub Date : 2025-06-26 DOI: 10.1002/art.43298

Chuan Fu Yap,Nisha Nair,Seema D Sharma,John Bowes,Amirah Binti Mohammad Ariff,Ann W Morgan,John D Isaacs,Anthony G Wilson,Kimme L Hyrich,Suzan Verstappen,James Bluett,Andrew P Morris,Anne Barton,Darren Plant,Sebastien Viatte

{"title":"Comparative Effectiveness of Abatacept versus Adalimumab in Shared Epitope positive and negative Rheumatoid Arthritis patients.","authors":"Chuan Fu Yap,Nisha Nair,Seema D Sharma,John Bowes,Amirah Binti Mohammad Ariff,Ann W Morgan,John D Isaacs,Anthony G Wilson,Kimme L Hyrich,Suzan Verstappen,James Bluett,Andrew P Morris,Anne Barton,Darren Plant,Sebastien Viatte","doi":"10.1002/art.43298","DOIUrl":"https://doi.org/10.1002/art.43298","url":null,"abstract":"OBJECTIVESThe effect of the shared epitope (SE), and valine at position 11 (Val11) of HLA-DRB1, on the activation of CD4+ T cells, is expected to be diminished by abatacept, a co-stimulation blocker. However, published evidence on the value of genetic stratification for abatacept treatment is conflicting. We aimed to compare the difference in effectiveness of abatacept and adalimumab in patients carrying the SE (or Val11).METHODSThe Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate is a nationwide observational cohort study recruiting patients from 53 centres across the UK before the initiation of biologic treatment and following them up prospectively for 12 months. 342 patients starting either on abatacept or adalimumab were eligible for this analysis. Serum drug levels for abatacept, adalimumab and methotrexate were determined at multiple time points. Multivariate modelling integrating demographic, clinical and pharmacological variables was used to test for associations between the number of copies of the SE or Val11 with response to treatment (EULAR response; DAS28 remission; change in DAS28). Differential effectiveness between drugs and genetic markers was assessed by the significance of their interaction term.RESULTSThere was no difference in the efficacy of abatacept versus adalimumab. We found weak evidence for an independent association of genetic markers with response to treatment (Val11 with EULAR response: p-value=0.02), but there was no significant difference in this effect between drugs.CONCLUSIONSWe find no evidence that HLA-typing is clinically useful to support prescription decisions for these two drugs.","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":"243 1","pages":""},"PeriodicalIF":13.3,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144488308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Response to "Comment on the Article by Lu et al." 回复“对Lu等人文章的评论”

IF 11.4 1区医学

Arthritis & Rheumatology Pub Date : 2025-06-23 DOI: 10.1002/art.43290

Yi Lu, Wenyu Xiao, Kun Tao

引用次数: 0

A Response to: Letter to the Editor Regarding "Efficacy and Safety of Zimlovisertib, Ritlecitinib and Tofacitinib, Alone and in Combination, in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate". 关于“Zimlovisertib、Ritlecitinib和Tofacitinib单独或联合用于中重度类风湿关节炎和甲氨蝶呤反应不足患者的疗效和安全性”的致编辑的回复。

IF 11.4 1区医学

Arthritis & Rheumatology Pub Date : 2025-06-23 DOI: 10.1002/art.43291

Spencer I Danto, Elena Peeva

引用次数: 0

A tolerogenic plasmid inhibits autoantibody production triggered by immunization with human peptidyl arginine deiminase 4. 耐受性原质粒抑制人肽基精氨酸脱亚胺酶4免疫引发的自身抗体的产生。

IF 13.3 1区医学

Arthritis & Rheumatology Pub Date : 2025-06-23 DOI: 10.1002/art.43295

Philippe P Pagni,Vijetha Kumar,Nathalie C Lambert,Eva Frison,Herve Luche,Marielle Mello,Magali Torres,Johnna D Wesley,Matthias von Herrath,Jean Roudier,Isabelle Auger

{"title":"A tolerogenic plasmid inhibits autoantibody production triggered by immunization with human peptidyl arginine deiminase 4.","authors":"Philippe P Pagni,Vijetha Kumar,Nathalie C Lambert,Eva Frison,Herve Luche,Marielle Mello,Magali Torres,Johnna D Wesley,Matthias von Herrath,Jean Roudier,Isabelle Auger","doi":"10.1002/art.43295","DOIUrl":"https://doi.org/10.1002/art.43295","url":null,"abstract":"OBJECTIVESRheumatoid arthritis (RA) is usually preceded and likely mediated by autoantibodies to citrullinated proteins (ACPAs) that recognize citrulline residues on multiple proteins. Conversion of arginine into citrulline is performed by enzymes called peptidyl arginine deiminases (PADs). We have previously demonstrated that the human PAD4 (hPAD4) is a T cell target whose recognition provides help for the production of ACPAs by a hapten/ carrier mechanism. Human PAD4 is thus an attractive therapeutic target to stop ACPA production. Here, we tested whether tolerization to hPAD4 may block the production of anti-citrullinated peptide antibodies.METHODSWe used a tolerogenic plasmid encoding hPAD4 and TGF-β1, IL-10, IL-2 in a model where C3H mice immunized with hPAD4 develop anti-citrullinated peptide antibodies. As controls, we used plasmid encoding TGF-β1, IL-10, IL-2 or a plasmid without hPAD4 nor cytokines. T cell activation in hPAD4-immunized mice injected with plasmids was analyzed by flow cytometry. Autoantibody profile was analyzed in hPAD4-immunized mice before and after plasmid injection by peptide array using 33 arginine-containing peptides and their 136 citrulline-substituted variants.RESULTSInjection of the plasmid encoding hPAD4 and TGF-β1, IL-10, IL-2 in hPAD4-immunized C3H mice significantly inhibited the T cell activation to hPAD4 and decreased antibody production to arginine and citrullinated peptides.CONCLUSIONSTolerizing to hPAD4 decreases the production of anti-citrullinated peptide antibodies in mice immunized with hPAD4. This suggests that tolerization to hPAD4 may allow to switch off ACPAs in RA.","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":"51 1","pages":""},"PeriodicalIF":13.3,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144370221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

EAT-lancet Diet Modifies the Risk of Rheumatoid Arthritis through Metabolomic Signature. EAT-lancet饮食通过代谢组学特征改变类风湿关节炎的风险

IF 11.4 1区医学

Arthritis & Rheumatology Pub Date : 2025-06-23 DOI: 10.1002/art.43297

Jin Feng, Chuyu Pan, Yifan Gou, Xuena Yang, Shiqiang Cheng, Wenming Wei, Guzhengyue Zheng, Huan Liu, Bolun Cheng, Yan Wen, Yumeng Jia, Feng Zhang

{"title":"EAT-lancet Diet Modifies the Risk of Rheumatoid Arthritis through Metabolomic Signature.","authors":"Jin Feng, Chuyu Pan, Yifan Gou, Xuena Yang, Shiqiang Cheng, Wenming Wei, Guzhengyue Zheng, Huan Liu, Bolun Cheng, Yan Wen, Yumeng Jia, Feng Zhang","doi":"10.1002/art.43297","DOIUrl":"https://doi.org/10.1002/art.43297","url":null,"abstract":"Objective: To investigate the association between the EAT-Lancet diet and rheumatoid arthritis (RA) and the underlying metabolic mechanisms.Methods: This prospective cohort study included 205,439 participants who were free of RA at baseline from the UK Biobank. The EAT-Lancet diet index was constructed based on dietary data collected via the Oxford WebQ. A metabolomic signature was developed using elastic net regression. The impact of the EAT-Lancet diet index and the metabolomic signature on the risk of incident RA was assessed using Cox proportional hazards models. Causal mediation analysis was performed to assess the mediating effects of the metabolomic signature and metabolites. A genome-wide gene-environment interaction study was conducted to identify genes interacting with the EAT-Lancet diet for RA.Results: Over a mean follow-up of 13 years, 1,897 RA cases were identified. The hazard ratios were 0.93 (95% CI: 0.90, 0.96) and 0.80 (95% CI: 0.70, 0.93) for 10-point increment of EAT-Lancet diet score and the corresponding metabolomic signature. The metabolomic signature mediated 34.07% (95% CI: 21.44%, 47.00%), primarily through pathways related to inflammation, fatty acids, and fluid balance. Key mediators included glycoprotein acetyls, docosahexaenoic acid, degree of unsaturation, omega-3 fatty acids, and albumin. Genes B2M, SLC30A4, SHF, SORD, CASC4, SPG11, CRIP2, BTBD6, and TEX22 were found to be interacted with the EAT-Lancet diet score.Conclusion: Greater adherence to the EAT-Lancet diet is linked to a reduced risk of RA, with significant mediation by the metabolomic signature, suggesting the potential of dietary interventions targeting specific metabolic pathways for RA prevention.","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":" ","pages":""},"PeriodicalIF":11.4,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144367693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comment on:Time‐dependent effect of prophylactic trimethoprim‐sulfamethoxazole on the incidence of serious infections in ANCA‐associated vasculitis: A target trial emulation study.

IF 13.3 1区医学

Arthritis & Rheumatology Pub Date : 2025-06-19 DOI: 10.1002/art.43296

Jan Willem Cohen Tervaert

引用次数: 0

Methodological Considerations for "Weight Reduction and Target Serum Urate Level:A Longitudinal Study of Annual Medical Examination" “减肥与目标血清尿酸水平：年度体检纵向研究”的方法学考虑

IF 13.3 1区医学

Arthritis & Rheumatology Pub Date : 2025-06-19 DOI: 10.1002/art.43292

Yiling Li, Jia Zhou

引用次数: 0

Global burden of osteoarthritis attributable to high body mass index, 1990-2021: insights from the Global Burden of Disease study 2021: Comment on the Article by Lu et al. 高体重指数导致的全球骨关节炎负担，1990-2021：来自全球疾病负担研究2021的见解：对Lu等人文章的评论

IF 13.3 1区医学

Arthritis & Rheumatology Pub Date : 2025-06-18 DOI: 10.1002/art.43288

Bi-Yu Gao,Chun-Chieh Chen,Shiuan-Chih Chen

引用次数: 0

Clonal sharing of CD8+ T-cells links skin and joint inflammation in psoriatic arthritis. CD8+ t细胞克隆共享与银屑病关节炎的皮肤和关节炎症有关。

IF 11.4 1区医学

Arthritis & Rheumatology Pub Date : 2025-06-17 DOI: 10.1002/art.43286

Lucy E Durham, Frances Humby, Nora Ng, Roman Laddach, Elizabeth H Gray, Sarah E Ryan, Kathryn J A Steel, Rosie Ross, Giovanni A M Povoleri, Rosamond Nuamah, Kathy Fung, Athul Menon Kallayil, Pawan Dhami, Bruce W Kirkham, Leonie S Taams

{"title":"Clonal sharing of CD8+ T-cells links skin and joint inflammation in psoriatic arthritis.","authors":"Lucy E Durham, Frances Humby, Nora Ng, Roman Laddach, Elizabeth H Gray, Sarah E Ryan, Kathryn J A Steel, Rosie Ross, Giovanni A M Povoleri, Rosamond Nuamah, Kathy Fung, Athul Menon Kallayil, Pawan Dhami, Bruce W Kirkham, Leonie S Taams","doi":"10.1002/art.43286","DOIUrl":"https://doi.org/10.1002/art.43286","url":null,"abstract":"Objective: Psoriatic arthritis (PsA) is an HLA class I-associated inflammatory arthritis that develops in up to 30% of people with psoriasis. We tested the hypothesis that skin and joint inflammation in PsA is linked in terms of CD8+ T-cell phenotype and clonality.Methods: Using scRNAseq (n=6 skin with n=5 paired synovial tissue and/or n=5 paired synovial fluid) and spatial transcriptomics (n=1 paired skin and synovial biopsies, n=4 unpaired biopsies), we compared the transcriptional signature, T-cell receptor repertoire and cell neighbourhoods of T-cells from skin and synovial tissue and/or fluid from patients with PsA.Results: We identified an enrichment of type-17 CD8+ tissue-resident memory (TRM) T-cells in both skin and joint, with a stronger IL-17 signature in the skin than the joint. CD8+ TRM cells resided in distinct cell neighbourhoods in skin and joint but were located adjacent to antigen-presenting cells in both sites. Several T-cell clones were shared between the skin and joint. Across the six patients, 155 CD8+ T-cell clones were shared between the two sites, comprising 1,071 CD8+ T cells and taking up a median of 13% of the skin and 8% of the joint CD8+ TCR repertoire. CD8+ skin-joint shared clones tended to have a similar phenotype at both sites, characterised by increased expression of genes associated with a cytotoxic, tissue-resident phenotype.Conclusion: Our findings support the hypothesis that skin and joint inflammation in PsA is linked in terms of CD8+ T-cell clonality and that specific T-cells migrate between these compartments to propagate inflammation across both sites.","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":" ","pages":""},"PeriodicalIF":11.4,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144315566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comment on "Efficacy and Safety of Zimlovisertib, Ritlecitinib and Tofacitinib, Alone and in Combination, in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate". 评论“Zimlovisertib、Ritlecitinib和Tofacitinib单独或联合治疗中重度类风湿关节炎和甲氨蝶呤反应不足的患者的疗效和安全性”。

IF 11.4 1区医学

Arthritis & Rheumatology Pub Date : 2025-06-16 DOI: 10.1002/art.43293

Ke Ma, Qiaoding Dai

引用次数: 0